AP2052A - Pseudopolymorphic forms of HIV protease inhibitor - Google Patents

Pseudopolymorphic forms of HIV protease inhibitor

Info

Publication number
AP2052A
AP2052A AP2004003191A AP2004003191A AP2052A AP 2052 A AP2052 A AP 2052A AP 2004003191 A AP2004003191 A AP 2004003191A AP 2004003191 A AP2004003191 A AP 2004003191A AP 2052 A AP2052 A AP 2052A
Authority
AP
ARIPO
Prior art keywords
protease inhibitor
hiv protease
pseudopolymorphic forms
pseudopolymorphic
forms
Prior art date
Application number
AP2004003191A
Other languages
English (en)
Other versions
AP2004003191A0 (en
Inventor
Hans Wim Pieter Vermeersch
Daniel Joseph Christiaan Thone
Luc Donne Marie-Louise Janssens
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29724454&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AP2004003191A0 publication Critical patent/AP2004003191A0/xx
Application granted granted Critical
Publication of AP2052A publication Critical patent/AP2052A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AP2004003191A 2002-05-16 2003-05-16 Pseudopolymorphic forms of HIV protease inhibitor AP2052A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02076929 2002-05-16
PCT/EP2003/050176 WO2003106461A2 (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of a hiv protease inhibitor

Publications (2)

Publication Number Publication Date
AP2004003191A0 AP2004003191A0 (en) 2004-12-31
AP2052A true AP2052A (en) 2009-10-05

Family

ID=29724454

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2004003191A AP2052A (en) 2002-05-16 2003-05-16 Pseudopolymorphic forms of HIV protease inhibitor

Country Status (25)

Country Link
US (8) US7700645B2 (es)
EP (4) EP2314591B2 (es)
JP (1) JP4864320B2 (es)
KR (2) KR101128370B1 (es)
CN (1) CN100475819C (es)
AP (1) AP2052A (es)
AU (2) AU2003271740B2 (es)
BR (1) BRPI0311176B8 (es)
CA (1) CA2485834C (es)
CY (3) CY1117928T1 (es)
DK (3) DK2314591T4 (es)
EA (1) EA007120B8 (es)
ES (4) ES2638412T3 (es)
HR (1) HRP20041061B1 (es)
HU (1) HUE034389T2 (es)
IL (1) IL165140A0 (es)
LT (1) LT2767539T (es)
MX (1) MXPA04011427A (es)
NO (1) NO331477B1 (es)
NZ (1) NZ536497A (es)
PL (1) PL215151B1 (es)
PT (3) PT2767539T (es)
SI (3) SI2314591T2 (es)
WO (1) WO2003106461A2 (es)
ZA (1) ZA200410154B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE500823T1 (de) 1998-06-23 2011-03-15 Us Of America Represented By The Secretary Dept Of Health And Human Services Arzneimittel zur behandlung von hiv-infizierten säugetieren
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
JP4818124B2 (ja) 2003-12-23 2011-11-16 テイボテク・フアーマシユーチカルズ・リミテツド （３Ｒ，３ａＳ，６ａＲ）−ヘキサヒドロフロ〔２，３−ｂ〕フラン−３−イル（１Ｓ，１Ｒ）−３−〔〔（４−アミノフェニル）スルホニル〕（イソブチル）アミノ〕−１−ベンジル−２−ヒドロキシプロピルカルバマートの製造方法
KR101333627B1 (ko) 2005-02-25 2013-11-27 얀센 알 앤드 디 아일랜드 프로테아제 저해제 전구체 합성
RU2464266C2 (ru) * 2006-11-09 2012-10-20 Тиботек Фармасьютикалз Лтд. СПОСОБЫ ПОЛУЧЕНИЯ ГЕКСАГИДРОФУРО[2,3-b] ФУРАН-3-ОЛА
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
MX2011007790A (es) * 2009-01-29 2011-11-18 Mapi Pharma Ltd Polimorfos de darunavir.
EP2477992B1 (en) * 2009-09-17 2016-12-14 Mylan Laboratories Limited Processes for the preparation of darunavir and the amorphous form thereof
EP2493891A2 (en) 2009-10-30 2012-09-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
PT2513116E (pt) * 2009-12-16 2015-10-14 Hetero Research Foundation Polimorfos de darunavir
EP2521728B1 (en) * 2010-01-05 2016-09-07 Cipla Limited Crystalline darunavir hydrate and process for preparation thereof
MX2012008627A (es) 2010-01-28 2012-09-21 Mapi Pharma Ltd Proceso para la preparacion de darunavir e intermedios de darunavir.
US8853430B2 (en) 2010-05-20 2014-10-07 Hetero Research Foundation Crystalline hydrochloride salt of darunavir
WO2012107889A1 (en) 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Process for the preparation of amorphous darunavir
SI2729130T1 (en) 2011-07-07 2018-03-30 Janssen Sciences Ireland Uc Combined formulations of darunavir
WO2013114382A1 (en) 2011-12-05 2013-08-08 Mylan Laboratories Ltd Crystalline darunavir
WO2013108105A2 (en) * 2012-01-18 2013-07-25 Aurobindo Pharma Limited Novel solvates of darunavir
CN103509031B (zh) * 2012-06-20 2016-04-27 上海迪赛诺药业有限公司 制备达芦那韦无定形物的方法
ES2848216T3 (es) * 2012-07-24 2021-08-05 Laurus Labs Ltd Un proceso para la preparación de Darunavir
CA2889903C (en) 2012-10-29 2021-03-09 Manjinder Singh Phull Antiviral phosphonate analogues and process for preparation thereof
US9346820B2 (en) * 2013-09-11 2016-05-24 Purdue Research Foundation HIV-1 protease inhibitors having gem-di-fluoro bicyclic P2-ligands
WO2016092525A1 (en) * 2014-12-12 2016-06-16 Lupin Limited Darunavir n-propanol solvate and process for preparation thereof
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
DK3271347T3 (da) 2015-03-19 2022-07-18 Mycovia Pharmaceuticals Inc Antifungale forbindelser og fremstillingsfremgangsmåder
WO2018029565A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited A multi-class anti-retroviral composition
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
ES2881949T3 (es) 2016-10-27 2021-11-30 Gilead Sciences Inc Forma cristalina de base libre de darunavir
CN108727401A (zh) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 达鲁那韦新晶型及其制备方法和应用
CN109053753A (zh) * 2018-08-05 2018-12-21 浙江大学 一种制备达卢那韦二水合物晶型的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006030A1 (en) * 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
WO1999067417A2 (en) * 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
JPH05230044A (ja) 1992-02-21 1993-09-07 Hoechst Japan Ltd ピレタニドの新規な結晶多形
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ATE194607T1 (de) * 1995-02-22 2000-07-15 Hoechst Japan Amorph piretanide, polymorphe davon, verfahren zur dessen herstellung und ihre verwendung
CO4940492A1 (es) * 1997-05-29 2000-07-24 Merck & Co Inc Inhibidor de proteasa de vih
GB9712253D0 (en) 1997-06-13 1997-08-13 Glaxo Group Ltd Antiviral compound
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
GB9805898D0 (en) * 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
GB9807354D0 (en) 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
US6225317B1 (en) 1998-11-19 2001-05-01 Dupont Pharmaceuticals Company Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1H)-quinazolinone
WO2000047551A2 (en) 1999-02-12 2000-08-17 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
EA007120B8 (ru) 2002-05-16 2012-03-30 Тиботек Фармасьютикалз Лтд. Псевдополиморфные формы ингибитора вич-протеазы
EP2521728B1 (en) * 2010-01-05 2016-09-07 Cipla Limited Crystalline darunavir hydrate and process for preparation thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006030A1 (en) * 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
WO1999067417A2 (en) * 1998-06-23 1999-12-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Fitness assay and associated methods

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Borka L et al *
Ghosh A K et al *
Giron et al *
Grunenberg A et al *

Also Published As

Publication number Publication date
US20170260196A1 (en) 2017-09-14
JP4864320B2 (ja) 2012-02-01
US20140171499A1 (en) 2014-06-19
DK1567529T3 (da) 2014-09-15
PL374321A1 (en) 2005-10-17
KR20050008715A (ko) 2005-01-21
DK2767539T3 (en) 2017-09-11
NO331477B1 (no) 2012-01-16
US20180312517A1 (en) 2018-11-01
US20050250845A1 (en) 2005-11-10
WO2003106461A2 (en) 2003-12-24
DK2314591T4 (da) 2021-05-10
IL165140A0 (en) 2005-12-18
SI2314591T1 (sl) 2014-11-28
CY1115665T1 (el) 2017-01-25
LT2767539T (lt) 2017-09-25
BRPI0311176B1 (pt) 2019-08-20
ES2503551T3 (es) 2014-10-07
US8518987B2 (en) 2013-08-27
EP2314591B1 (en) 2014-06-18
PT2767539T (pt) 2017-08-28
ES2498370T5 (es) 2021-11-24
AU2003271740A1 (en) 2003-12-31
DK2314591T3 (da) 2014-09-22
PL215151B1 (pl) 2013-10-31
HRP20041061B1 (hr) 2015-02-27
AP2004003191A0 (en) 2004-12-31
SI2767539T1 (sl) 2017-10-30
DK1567529T4 (da) 2021-05-10
CY1119311T1 (el) 2018-02-14
ES2638412T3 (es) 2017-10-20
EP2767539B1 (en) 2017-07-12
ES2728735T3 (es) 2019-10-28
EP2314591A1 (en) 2011-04-27
CA2485834C (en) 2007-07-17
ES2498370T3 (es) 2014-09-24
HRP20041061A2 (en) 2006-07-31
ZA200410154B (en) 2005-12-28
EA007120B1 (ru) 2006-06-30
KR101128370B1 (ko) 2012-04-23
CY1117928T1 (el) 2017-05-17
EP1567529B2 (en) 2021-02-24
HK1081969A1 (en) 2006-05-26
ES2503551T5 (es) 2021-10-28
PT2314591E (pt) 2014-09-19
EP1567529A2 (en) 2005-08-31
EP1567529B1 (en) 2014-06-18
EA007120B8 (ru) 2012-03-30
HUE034389T2 (en) 2018-02-28
SI1567529T1 (sl) 2014-11-28
EP2767539A1 (en) 2014-08-20
SI2314591T2 (sl) 2021-08-31
PT1567529E (pt) 2014-09-09
US20150336980A1 (en) 2015-11-26
US20130303790A1 (en) 2013-11-14
WO2003106461A3 (en) 2004-05-13
US10000504B2 (en) 2018-06-19
AU2003271740B2 (en) 2010-05-13
NZ536497A (en) 2006-08-31
SI1567529T2 (sl) 2021-08-31
CN100475819C (zh) 2009-04-08
BRPI0311176B8 (pt) 2021-05-25
CN1668623A (zh) 2005-09-14
US20210179631A1 (en) 2021-06-17
US10858369B2 (en) 2020-12-08
US7700645B2 (en) 2010-04-20
CA2485834A1 (en) 2003-12-24
JP2005533068A (ja) 2005-11-04
MXPA04011427A (es) 2005-02-17
EA200401503A1 (ru) 2005-06-30
EP3045460B1 (en) 2019-04-17
EP2314591B2 (en) 2021-02-24
US20100204316A1 (en) 2010-08-12
NO20045409L (no) 2004-12-10
KR20100119906A (ko) 2010-11-11
BR0311176A (pt) 2005-03-15
EP3045460A1 (en) 2016-07-20
AU2012205289A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
AP2052A (en) Pseudopolymorphic forms of HIV protease inhibitor
PL375486A1 (en) Potent inhibitor of hcv serine protease
GB0125445D0 (en) Protease Inhibitors
EP1549316A4 (en) HAMMER OF TFGbeta
AU2003213776A1 (en) Carbamates as hiv protease inhibitors
EP1483254A4 (en) INHIBITORS OF ANTI-RESISTANCE RETROVIRAL PROTEASE
IL165475A0 (en) Nitrooxyderivatives of eyclooxygenase-2 inhibitors
AU2003277891A1 (en) Hcv ns-3 serine protease inhibitors
AU2003269984A8 (en) Protease inhibitors
EP1401453A4 (en) PROTEASE INHIBITORS
AU2003287325A8 (en) N-cycloalkylglycines as hiv protease inhibitors
AU2003263738A8 (en) Protease inhibitors
AU2001280634A1 (en) Salt forms of an hiv protease inhibitor
GB0123467D0 (en) Carbocyclic HIV Protease inhibitors
AU2002305720A1 (en) Piperazine pentanamide hiv protease inhibitors
AU2003304496A8 (en) Protease inhibitors
GB0200479D0 (en) Fluorogenic protease substrates
AU2003233642A8 (en) Protease inhibitors
IL160626A0 (en) Antiviral protease inhibitors
AU2003252417A1 (en) Protease inhibitor
ZA200500560B (en) Potent inhibitor of HCV serine protease
AU2003265240A8 (en) Protease inhibitors
AU2003269878A8 (en) Protease inhibitors
AU2002255485A8 (en) Hiv/fiv protease inhibitors
GB0104691D0 (en) Enzyme inhibitor